MHub, 1817, the Polsky Center and dozens more Chicago tech organizations are seizing the moment during the DNC to show the world what they're working on.

The Glen Ellyn-based company has tripled its revenue in the last year, riding a wave of alternative staffing solutions that has emerged since the pandemic disrupted traditional work arrangements.

The six-month program is designed for startups seeking support with product development and commercialization.

Manufacturing and hard tech incubator mHub is launching another medical technology accelerator to find and foster health care startups.

Immersive virtual reality can help create simulated scenes that mirror the real world and simplify it, says Floreo CEO Vijay Ravindran. That is why VR is beneficial for teaching neurodiverse individuals life skills.

Vijay Ravindran, founder of autism therapy digital therapeutic firm Floreo, spoke to Medtech Insight about working with the FDA, and why the TAP pilot made sense for them.

Isabel Casillas Guzman, head of the U.S. Small Business Administration (SBA), traveled to Chicago, including mHUB, to attend Opportunity Finance Network’s (OFN) Small Business Finance Forum, celebrate Pride Month, and kick off the SBA’s Small Business Boom tour.

The Cognitive Ability Assessment Market from Orbis Research highlights Winterlight Labs as one of the key players in the space.

Bedrock Materials, a pioneering battery technology startup launched out of Stanford University in 2023, has announced a successful close of $9 million in seed funding alongside the inauguration of its new Research & Development (R&D) headquarters in Chicago, Illinois, with its temporary headquarters at mHUB,

Winterlight Labs launched AQUA, our automated quality assurance solution for clinical trials, powered by their speech and language technology. AQUA enables quality assurance of clinical assessments and ratings to be conducted more quickly, economically and accurately.

Leaders from Fortune 500 companies, tech start-ups, and universities joined Governor JB Pritzker Monday to announce a plan to make Chicago the nation’s “quantum technology capital” at M-Hub, a business incubator on Chicago’s Near West Side.

Yobee presented at the Health & Wellness Women in TechRise Chicago Competition, highlighting pioneering women founders, on April 12th.

Autism treatment has been a frequent target of private-equity disruption, but it's less common to see a health system's venture arm wade into the space.

Computational speech features analyzed with Winterlight Labs speech technology, are sensitive to symptom severity in first-episode psychosis.

Yobee was one of 16 Chicagoland CEOs giving 1-minute elevator pitches on April 2, 2024, at the Start-up Showcase & Board Member Match-up event at the Women in Bio (WIB) - 3.8 Initiative at Portal Innovations, LLC.

Ikaika was one of 16 Chicagoland CEOs giving 1-minute elevator pitches on April 2, 2024, at the Start-up Showcase & Board Member Match-up event at the Women in Bio (WIB) - 3.8 Initiative at Portal Innovations, LLC.

The Phoenix Center, a school for kids with disabilities, is using virtual reality to try to ease the journey of airport travel by leveraging Floreo's VR technology and the Meta Quest 2 headset.

Cambridge Cognition, which acquired Winterlight Labs in 2023, establishes a Scientific Advisory Board comprising experts in cognitive science and clinical trials to guide the integration of emerging trends like blood-based biomarkers and collaborative assessments.

Winterlight Labs' speech technology has demonstrated the ability to characterize speech features as phenotypic characteristics to accurately predict the transition from cognitively unimpaired to cognitively impaired.

Vivoryon Therapeutics N.V. is conducting an in-depth analysis of their Phase 2b results, including analyses of additional pre-specified exploratory endpoints (e.g. Winterlight Labs speech assessment) and distinct patient cohorts as defined in the statistical analysis plan.

New research shows talking speed might be a more telling indicator of cognitive decline and dementia than the occasional struggle to find words, with methods including analyzing speech patterns with AI-based software developed in collaboration with Winterlight Labs.

Winterlight Labs hosted a workshop that included several keynote and panel talks on a range of important topics relevant to advancing multi-modal machine learning applications in clinical health, including speech analysis.

Researchers used Winterlight's speech biomarker technology to explore how speech biomarkers could be leveraged to automatically detect CDR administration variances in Alzheimer’s disease (AD) clinical trials.

Using Winterlight's speech biomarker technology, the study found that sensitivity of remote VPA-LORE to sleepiness and independence from age may benefit AD research that looks for effects on sleep and on memory processes that are independent of age.

The study's cross-task measures, which used Winterlight's speech biomarker technology, have potential to serve as a cognitive biomarker for the early stages of AD and other neurodegenerative or psychiatric pathologies.

ActiGraph and Cambridge Cognition, leading providers of wearable digital health technologies and CNS assessments, respectively, announced a new strategic partnership to deliver a broad suite of assessments to provide a fully-rounded view of mental and physical capabilities. The companies’ technologies have been used together by top 20 pharma companies in clinical trials already.

Automated acoustic analysis using a pipeline developed by Winterlight Labs can detect bulbar ALS, as well as earlier stages of the disease. These results show that even with a relatively small set of acoustic features, the Winterlight pipeline could stratify ALS patients into early and late bulbar stages, with clinically-interpretable feature importances.

Yobee was featured in the Northwestern Journal talking about Yobee, a scalp-relief startup safe and effective for kids and adults.

This novel, automated speech assessment feature set, which utilized Winterlight Labs' speech technology, demonstrates substantial promise as a valid tool for analyzing impaired speech in ALS patients and for the further development of these technologies.

Winterlight's machine learning team has been evaluating the generalizability and robustness of large language models for detecting AD from speech, in order to determine the most promising models to leverage for clinical use cases. They presented a recent comparison of models trained on speech from a picture description task at the 2023 Conference on Empirical Methods in Natural Language Processing (EMNLP).

Remote digital speech assessments, including the Winterlight Assessment (WLA), have the potential to characterize speech and language abilities in individuals with FTD, reducing the burden of clinical assessments while providing a novel measure of speech and language abilities that is sensitive to disease and relevant to everyday function.

The Chicago Biomedical Consortium showcased promising new biotech innovations at the Chicago BioCapital Summit that took place at Portal Innovations on November 2, 2023, including Ikaika's own CSO Dr. Alexis Demonbreun speaking about Ikaika's anti-fibrotic biologic technology.

Yobee published their second clinical trial with our ScalpMask in pediatrics in Clinical, Cosmetic and Investigational Dermatology, demonstrating that Yobee is safe and effective for kids and adults

The NIH National Institute on Aging awarded Grove Biopharma, Inc non-dilutive funding for their Nrf2 biologics treating neurodegenerative diseases.

Geneius Biotechnology, Inc., an immuno-oncology company developing a best-in-class personalized RNA-enabled T cell therapy platform for solid and liquid cancers, announced they will present at the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting.

Winterlight is continuing work on advancing speech biomarkers in ALS and FTD through an ongoing consortium study funded by TargetALS and including researchers from ki:elements and the German Center for Neurodegenerative Diseases (DZNE).

In line with the recent launch of their AQUA solution for QA in clinical trials, Winterlight Labs has been developing approaches to enhance the efficiency, affordability, and scalability of QA for clinical trials. In a poster presented at the 2023 ISCTM Annual Scientific meeting, they showed high agreement between expert and non-expert reviewers for identifying common administration issues during the ADAS-Cog assessment.

Over the years, we have had many different types of requested Floreo experiences and a lot of them have made it into the app already!